Effect of diosimin combined with ulinastatin on renal injury markers and renal ultrasound indicators in patients with delayed renal function recovery after transplantation

Abstract

Abstract Backgroud: Renal transplantation, as an effective treatment for end-stage renal disease, has many clinical complications, among which delayed graft function recovery (DGF), as one of the common postoperative complications, is also a major risk factor affecting the short-term and long-term efficacy of renal transplantation. Therefore, reasonable use of DGF after renal transplantation to promote renal function recovery is of great significance for the prognosis of these patients. Methods: Based on this, 62 patients who underwent renal transplantation and developed DGF in our hospital from June 2018 to December 2021 were selected as the research objects. According to the random color method, they were divided into three groups: diosimin group (n=20), ulinastatin group (n=21), and combination group (n=21). To observe the effects of different medication regimens on renal injury markers and renal ultrasound related indexes in patients with DGF, and to lay a theoretical foundation for guiding clinical medication and improving prognosis of DGF patients. Results: After comparing the general data of the three groups, it was found that there was no significant difference (P > 0.05), indicating that there was no difference in medication results due to personal factors. The levels of Scr, CysC and BUN in the ulinastatin group after treatment were significantly better than those before treatment. The levels of renal injury markers in the combined group were significantly better after treatment than before treatment. According to the ultrasound results, there was no significant difference in the renal ultrasound indexes between the diosimine and ulinastatin groups after treatment, while the renal ultrasound indexes of the combined group were better than those of the other two groups. Conclusion: It can be concluded from the results that diosimin combined with ulinastatin can significantly reduce renal injury in patients with DGF, and can effectively improve renal function in such patients, which has a positive effect on improving prognosis.